

# REVENIO

## Revenio Group Corporation: Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act

Revenio Group Corporation | Stock Exchange Release | February 14, 2025 at 16:00:00 EET

Revenio Group Corporation has received the following notification pursuant to Chapter 9, section 5 of the Securities Markets Act ("SMA"), according to which William Demant Invest A/S voting rights in Revenio Group exceeded above 20 percent on February 13, 2025.

Total position of William Demant Invest A/S according to the notification:

	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both in %	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	20.02742%		20.02742%	26,681,116
Position of previous notification (if applicable)	15.10%		15.10%	

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights

Class/type of shares, ISIN code	Number of shares and voting rights		% of shares and voting rights	
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
Fl0009010912	5,343,539	-	20.02742%	-
<b>SUBTOTAL A</b>	<b>5,343,539</b>		<b>20.02742%</b>	

# REVENIO

---

**For further information, please contact**

CFO Robin Pulkkinen, tel. +358 50 505 9932

[robin.pulkkinen@revenio.fi](mailto:robin.pulkkinen@revenio.fi)

**Distribution**

Nasdaq Helsinki Ltd

Financial Supervisory Authority (FIN-FSA)

Main media

[www.reveniogroup.fi/en](http://www.reveniogroup.fi/en)

**Revenio Group in brief**

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2024, the Group's net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

**Attachments**

---

[Revenio Group Corporation: Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act](#)